BioNxt Solutions Inc. BNXT
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -99.37% | -99.40% | -99.49% | -62.78% | -30.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.37% | -99.40% | -99.49% | -62.78% | -30.40% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -99.37% | -99.40% | -99.49% | -62.78% | -30.40% |
| SG&A Expenses | 48.16% | 65.62% | 69.09% | 37.13% | 42.26% |
| Depreciation & Amortization | -75.00% | -71.83% | -88.08% | -74.39% | -66.54% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.28% | 40.29% | 29.30% | -5.21% | 0.42% |
| Operating Income | -27.81% | -40.95% | -30.09% | 4.76% | -0.60% |
| Income Before Tax | -54.48% | -65.65% | -30.83% | 6.18% | 7.52% |
| Income Tax Expenses | -120.90% | -120.90% | -120.90% | -- | -- |
| Earnings from Continuing Operations | -53.50% | -64.79% | -29.35% | 7.53% | 8.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.50% | -64.79% | -29.35% | 7.53% | 8.87% |
| EBIT | -27.81% | -40.95% | -30.09% | 4.76% | -0.60% |
| EBITDA | -29.43% | -43.25% | -31.94% | 4.36% | -1.29% |
| EPS Basic | -42.18% | -53.19% | -21.78% | 13.21% | 16.22% |
| Normalized Basic EPS | -30.34% | -38.22% | -18.39% | 9.62% | 12.36% |
| EPS Diluted | -42.18% | -53.19% | -21.78% | 13.21% | 16.22% |
| Normalized Diluted EPS | -30.34% | -38.22% | -18.39% | 9.62% | 12.36% |
| Average Basic Shares Outstanding | 8.05% | 6.49% | 5.80% | 5.76% | 8.21% |
| Average Diluted Shares Outstanding | 8.05% | 6.49% | 5.80% | 5.76% | 8.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |